TITLE

Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS

AUTHOR(S)
Berrey, M. Michelle; Schacker, Timothy; Collier, Ann C.; Shea, Theresa; Brodie, Scott J.; Mayers, Douglas; Coombs, Robert; Krieger, John; Chun, Tae-Wook; Fauci, Anthony; Self, Steven G.; Corey, Lawrence
PUB. DATE
May 2001
SOURCE
Journal of Infectious Diseases;5/15/2001, Vol. 183 Issue 10, p1466
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the clinical benefits of antiretroviral therapy in primary HIV type 1 infection. Virologic response to antiretroviral therapy; Effect of combination antiretroviral therapy on CD4... T cells; Adverse events and adherence to medications.
ACCESSION #
4470960

 

Related Articles

  • T Cell Dynamics and the Response to HAART in a Cohort of HIV-1-Infected Elite Suppressors. Sedaghat, Ahmad R.; Rastegar, Darius A.; O'Connell, Karen A.; Dinoso, Jason B.; Wilke, Claus O.; Blankson, Joel N. // Clinical Infectious Diseases;12/1/2009, Vol. 49 Issue 11, p1763 

    Elite controllers or suppressors are untreated human immunodeficiency virus type 1 (HIV-1)-infected patients who maintain undetectable viral loads. In this study, we show that most elite suppressors do not experience significant changes in T cell counts over a 10-year period. Interestingly,...

  • Activity of the Combination of Nelfinavir and Saquinavir Against Human Immunodeficiency Virus After Failure of Prior Protease Inhibitor Therapy. Kravcik, Stephen; Victor, Gary; Angel, Jonathan B.; Badley, Andrew D.; Cameron, D. William // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p702 

    Reports on the effectiveness of combining nelfinavir and saquinavir for the treatment of HIV infections. Details of a retrospective study on HIV-positive patients prescribed with nelfinavir and saquinavir; Effects of the drugs on the viral levels of the patients; Importance of treatment changes...

  • A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1. Saag, Michael; Goodrich, James; Fätkenheuer, Gerd; Clotet, Bonaventura; Clumeck, Nathan; Sullivan, John; Westby, Mike; van der Ryst, Elna; Mayer, Howard // Journal of Infectious Diseases;6/1/2009, Vol. 199 Issue 11, p1638 

    Background. Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in...

  • Additional Reports of Failure to Respond to Treatment After Rabies Exposure in Thailand. Hemachudha, Thiravat; Mitrabhakdi, Erawady; Wilde, Henry; Vejabhuti, Apirom; Siripataravanit, Somporn; Kingnate, Darika // Clinical Infectious Diseases;1/1/1999, Vol. 28 Issue 1, p143 

    Focuses on additional reports of failure to respond to treatment after rabies exposure in Thailand. Deviations from treatment recommendations; Autopsy-confirmed deaths due to rabies; Postexposure rabies treatment.

  • AIDS: A Review of Targets and Approaches for Treatment. Gupta, S. D.; Ramteke, Suman; Gupta, A.; Moorthy, N. S. H. N. // Indian Journal of Pharmaceutical Sciences;2007, Vol. 69 Issue 2, p173 

    Untreated HIV infection is characterized by a gradual deterioration of immune function. Most notably, crucial immune cells known as CD4 positive T lymphocytes are disabled and killed during the typical course of infection. These T lymphocyte cells play central role in the immune response. The...

  • Are We Done Monkeying Around With TRIM5α? Campbell, Edward // Molecular Therapy;Jun2014, Vol. 22 Issue 6, p1072 

    The author discusses aspects of the stabilization of human tripartite motif-containing protein 5 (TRIM5) alpha protein which restrict the human immunodeficiency virus (HIV-1) infection in human T cells. He states that TRIM5 alpha has the ability to inhibit the infection between the member of...

  • Science Translational Medicine: Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article offers information on the report published in Science Translational Medicine regarding the treatment of patients infected with Human Immunodeficiency Virus (HIV) with genetically modified T cell therapy.

  • Stabilized Human TRIM5α Protects Human T Cells From HIV-1 Infection. Richardson, Max W; Guo, Lili; Xin, Frances; Yang, Xiaolu; Riley, James L // Molecular Therapy;Jun2014, Vol. 22 Issue 6, p1084 

    Rhesus (rh) but not human (hu) TRIM5α potently restricts human immunodeficiency virus (HIV)-1 infection. It is not clear why huTRIM5α fails to effectively block HIV infection, but it is thought to have a lower affinity for the viral core. Using primary human CD4 T cells, we investigated...

  • TO THE EDITOR. Freeman, Michael L.; Mudd, Joseph C.; Shive, Carey L.; Younes, Souheil-Antoine; Panigrahi, Soumya; Sieg, Scott F.; Lee, Sulggi A.; Hunt, Peter W.; Calabrese, Leonard H.; Gianella, Sara; Rodriguez, Benigno; Lederman, Michael M. // Clinical Infectious Diseases;6/1/2016, Vol. 62 Issue 11, p1468 

    A response from the authors of the article "CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection" in the 2016 issue is presented.

  • Proliferative Responses to Human Immunodeficiency Virus Type 1 (HIV-1) Antigens in HIV-1-Infected Patients with Immune Reconstitution. Blankson, Joel N.; Gallant, Joel E.; Siliciano, Robert F. // Journal of Infectious Diseases;2/15/2001, Vol. 183 Issue 4, p657 

    Features a study on human immunodeficiency virus type 1 (HIV-1)-specific CD4 T cell proliferative responses in HIV-1-infected patients who began highly active antiretroviral therapy with low CD4 cell count nadirs and experienced immune reconstitution. Background of the CD4 T cells; Patients and...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics